Chimeric lyssavirus nucleic acids and polypeptides

Details Chimeric lyssavirus nucleic acids and polypeptides Chimeric lyssavirus nucleic acids and polypeptides

2007-06-26

2007-06-26

Campell, Bruce R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S202100, C424S192100, C434S069000

Reexamination Certificate

active

10608538

ABSTRACT:
The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode chimeric immunogenic polypeptides. The nucleic acids encode at least site III of a lyssavirus glycoprotein, which has been found to improve the immunogenicity of lyssavirus epitopes for protection from rabies. The chimeric nucleic acids and proteins can also contain antigenic determinants for epitopes other than those of lyssavirus. Thus, the invention provides chimeric nucleic acids and polypeptides that elicit a strong immune response to multiple antigens. Use of the methods of the present invention permits DNA vaccination without the need to supply multiple antigens on separate DNA molecules.

REFERENCES:
patent: 6673601 (2004-01-01), Jacob et al.
patent: 696 191 (1994-10-01), None
patent: WO 90 11092 (1990-10-01), None
patent: WO 93 06223 (1993-04-01), None
patent: WO 95/09249 (1995-04-01), None
Wojczyk et al. Protein expression and purification 1996, vol. 7, pp. 183-193.
Tordo et al. Virol. 1993, vol. 14, No. 1, pp. 59-69.
Fekadu et al. Vaccine 1988, vol. 6, No. 6, pp. 533-539.
Lafon et al. Vaccine 1988, vol. 6, No. 4, pp. 362-368.
Wunner et al. Ann. Ins. Pasteur/Virol. 1985, vol. 136E, pp. 353-362.
Bahloul et al. Vaccine 1998, vol. 16, No. 4, pp. 417-425.
Jallet et al. J. Virol. 1999, vol. 73, No. 1, pp. 225-233.
U.S. Appl. No. 09/958,672, filed Apr. 17, 2000, Jacob et al.
Amengual, B. et al., “Evolution of European Bat Lyssaviruses”,J. Gen. Virol., 78:2319-2328 (1997).
Bahloul, C. et al., “DNA-based Immunization for Exploring the Enlargement of Immunological Cross-reactivity Against the Lyssaviruses”,Vaccine, 16:417-425 (1998).
Benmansour et al., “Antigenicity of Rabies Virus Glycoprotein”,J. Virol., 65(8):4198-4203 (1991).
Buffett et al., “P. falciparumDomain Mediating Adhesion to Chondroitin Sulfate A: A Receptor for Human Placental Infection”,PNAS, 96(22):12743-48 (1999).
Coulon et al., “An Avirulent Mutant of Rabies Virus is Unable to Infect Motoneurons In Vivo and In Vitro”,J. Virol., 72(1):273-278 (1998).
Desméziéres et al.; Lyssavirus glycoproteins expressing immunologically potent foreign B cell and cytotoxic T lymphocyte epitopes as prototypes for multivalent vaccines; J. Gen. Virol. (1999), 80:2343-2351.
Dietzschold et al., “Structural and Immunological Characterization of a Linear Virus-Neutralizing Epitope of the Rabies Virus Glycoprotein and its Possible Use in a Synthetic Vaccine”,Vaccine, 64(8):3804-3809 (1990).
Donnelly, J. et al., “DNA Vaccines”,Annu. Rev. Immunol., 15:617-648 (1997).
Ertl., et al., “Novel Vaccine Approaches”,Journal of Immunology, 156:3579-3582 (1996).
European Commission COST/STD-3, “Advantages of Combined Vaccines”,Vaccine, 14(7):693-700 (1996).
Gaudin, Y., et al., “Reversible Conformational Changes and Fusion Activity of Rabies Virus Glycoprotein”,J. Virol., 65(9):4853-4859 (1991).
Gaudin, Y. et al., “Biological Function of the Low-pH, Fusion-inactive Conformation of Rabies Virus Glycoprotein (G): G is Transported in a Fusion-inactive State-like Conformation”,J. Virol., 69(9):5528-5533 (1995).
Gaudin, Y., “Folding of Rabies Virus Glycoprotein: Epitope Acquisition and Interaction with Endoplasmic reticulum Chaperones”,J. Virol., 71(15):3742-3750 (1997).
Jallet et al., “Chimeric Lyssavirus Glycoproteins with Increased Immunological Potential”,Journal of Virology, 73(1):225-233 (1999).
Lafay et al., “Immunodominant Epitopes Defined by a Yeast-expressed Library of Random Fragments of the Rabies Virus Glycoprotein Map Outside Major Antigenic Sites”,J.Gen. Virol., B77:339-346 (1996).
Lafon et al., “Antigenic Sites on the CVS Rabies Virus Glycoprotein: Analysis with Monoclonal Antibodies”,J. Gen. Virol., 64:843-845 (1983).
Lafon, M. et al., “Use of a monoclonal Antibody for Quantitation of Rabies Vaccine Glycoprotein by Enzyme Immunoassay”,J. Biol. Standard, 13:295-301 (1985).
Lang, J. et al., “Randomised Feasibility Trial of Pre-Exposure Rabies Vaccination with DTP-IPV in Infants”,The Lancet, 349:1663-1665 (1997).
Liu et al., “Polynucleotide Vaccines:A Potential New Generation of Vaccines,”Proc. Eur. Assoc. Vet. Pharmacol. Toxicol. 6 Meet., 301, Abstract Only (1994).
Lodmell, D. et al., “DNA Immunization Protects Nonhuman Primates Against Rabies Virus”,Nature Med., 4(8):949-952 (1998a).
Lodmell, D. et al., “Gene Gun Particle-Mediated Vaccination with Plasmid DNA Confers Protective Immunity Against Rabies Virus Infection”,Vaccine, 16(2/3):115-118 (1998b).
MacFarlan, R. et al., “T Cell Responses to Cleaved Rabies Glycoprotein and to Synthetic Peptides”,J. Immunol., 133(5):2748-2752 (1984).
Macy et al.,Vet. Clin. North Am small Anim. Pract., Abstract Only, 26(1):103-109 (1996).
Mebatsion et al., “Mokola Virus Glycoprotein and Chimeric Proteins Can Replace Rabies Virus Glycoprotein in the Rescue of Infectious Defective Rabies Virus Particles”,Journal of Virology, 69(3):1444-1451 (1995).
Paoletti et al.,PNAS, 93(21):11349-53 (1996).
Pastoret, P-P. et al., “Vaccination Against Rabies”,In Veterinary Vaccinologyl, Pastoret, Eds. (Elsevier):616-628 (1997).s.
Perrin, P. et al., “Rabies Immunosome (Subunit Vaccine) Structure and Immunogenicity”,Vaccine, 3:325-332 (1985).
Perrin, P. et al., “The Influence of the Type of Immunosorbent on Rabies Antibody EIA: Advantages of Purified Glycoprotein over Whole Virus”,J. Biol. Standard, 14:95-102 (1986).
Perrin, P. et al. Interleukin 2 increases protection against experimental rabies, Immunobiology, vol. 177, pp. 199-209 (1988).
Perrin, P., “Techniques for the Preparation of Rabies Conjugates”,In Laboratory Techniques in Rabies, 4thEd. (Eds Meslin, F-X; Kaplan, M. and Koprowski, H.) WHO, Geneva:433-445 (1996a).
Perrin, P. et al., “The Antigen-Specific Cell-Mediated Immune Response in Mice is Suppressed by Infection with Pathogenic Lyssaviruses”,Res. Virol., 147:289-299 (1996b).
Rogers, S., et al., Amino acid sequences common to rapidly degraded proteins: The PEST hypothesis, Science, vol. 234, pp. 364-369 (1986).
Smith, J. et al., “A Rapid Fluorescent Focus Inhibition Test (RFFIT) for Determining Virus-Neutralizing Antibody”,In Laboratory Techniques in Rabies, 4thEd. (Eds Meslin, F-X; Kaplin, M. and Koprowski, H.) WHO, Geneva:181-189 (1996).
Thomson, S. et al., “Delivery of Multiple CD8 Cytotoxic Cell Epitopes by DNA Vaccination”,J. Immunol., 160(4):1717-1723 (1998).
Tine et al., “NYVAC-Pf7:A Poxvirus-vectored, Multiantigen, Multistage Vaccine Candidate for Plasmodium Falciparum Malaria,”Infection and Immunity., 64(9):3833-3844 (1996).
Tuffereau et al., “Neuronal Cell Surface Molecules Mediate Specific Binding to Rabies Virus Glycoprotein Expressed by a Recombinant Baculovirus on the Surfaces of Lepidopteran Cells”,J. Virol., 722):1085-1091 (1998).
Wunner, W. et al., “Localization of Immunogenic Domains on the Rabies Virus Glycoprotein,”Ann. Inst. Pasteur, 136E:353-362 (1985).
Xiang, Z. et al., “Vaccination with a Plasmid Vector Carrying the Rabies Virus Glycoprotein Gene Induces Protective Immunity Against rabies Virus”,Virol., 199:132-140 (1994).

Affiliated with

Also associated with

Rating

Chimeric lyssavirus nucleic acids and polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chimeric lyssavirus nucleic acids and polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric lyssavirus nucleic acids and polypeptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3814726